Sanford Burnham Prebys scientists have identified a natural defence that appears to blunt one of Alzheimer’s most destructive features: toxic tau build-up. In mouse experiments reported on July 17, 2026 in Science Advances, higher levels of the protein SORLA were linked with less tau accumulation, reduced brain shrinkage and healthier connections between neurons. Animals lacking SORLA, by contrast, showed more extensive damage.
Natural brake on tau pathology
Under normal conditions, tau helps stabilise microtubules — the internal scaffolding that supports neuron shape and function. In Alzheimer’s and related tauopathies, tau proteins misfold and clump inside nerve cells, disrupting circuits and correlating with cognitive decline. The team examined whether SORLA — short for sorting-related receptor with A-type repeats — could counter this process.
“In the last 15 or 20 years, considerable data has come out from our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer’s disease — amyloid-beta generation and accumulation,” said Timothy Huang, PhD, assistant professor in the Center for Neurologic Diseases at Sanford Burnham Prebys. “Very little was known, however, about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer’s disease.”
What the mouse model revealed
To probe SORLA’s impact, researchers crossbred mice engineered to produce elevated human SORLA with animals that typically develop tau tangles, brain atrophy and learning deficits. This combined model allowed the team to observe whether additional SORLA could alter the course of tau accumulation and downstream neurodegeneration. The study found that raising SORLA levels interfered with several steps that lead to tangled tau and its damaging consequences.
- More SORLA: less tau aggregation, less atrophy, more intact synaptic connections.
- Less or no SORLA: greater tau burden and more severe neurodegenerative changes.
| Condition | Tau accumulation | Brain structure | Neuronal connectivity |
|---|---|---|---|
| Elevated SORLA | Reduced | Preserved | Healthier |
| Absent/low SORLA | Increased | More atrophy | Compromised |
Two sides of Alzheimer’s pathology
Most Alzheimer’s research has focused on amyloid-beta plaques, and earlier work from Huang’s group and others linked SORLA to reduced amyloid generation and accumulation. The new findings extend that line of evidence to the disease’s other core lesion — tau tangles — suggesting SORLA may influence both of the disorder’s defining pathologies. By strengthening an endogenous protective pathway, future treatments might be able to dampen tau toxicity while potentially complementing anti-amyloid strategies.
Why it matters and what’s next
Drugs directly targeting tau have faced challenges, and not all amyloid-focused treatments address the full spectrum of neurodegeneration. Modulating a receptor like SORLA could open a parallel route: enhancing the brain’s own sorting and protective mechanisms to limit tau’s cascade of harm. While these results come from a mouse model, the work identifies a clear biological foothold for preclinical development and mechanistic studies aimed at translating a SORLA-based approach.
Alzheimer’s and related tau-driven diseases exert their toll by hollowing out neuronal networks over time. The observation that increased SORLA coincided with healthier synapses and less atrophy is a notable signal that deserves rigorous follow-up, including validation in additional models and eventual clinical exploration. For now, the research adds a carefully drawn map point: amplifying SORLA’s activity may be one way to reroute the course of tau pathology before it dismantles brain circuits.
